Dr Morro Touray is a Health Economist with extensive background in development works. He holds a postgraduate diploma in Health Policy, Planning and Finance (HPPF) from London School of Hygiene and Tropical (2006), MSc in Development Management (with distinction) from Glasgow Caledonian University (1999), MSc in HPPF from London School of Economics and Political Science (2006) and a PhD in Health Economics from University of South Wales (2018).
He previously worked in various countries and for many organisations including Action Aid, Medical Research Council (UK) Laboratories, United Nations Development Programme (UNDP), University of South Wales and Swansea University. He has been involved in many multidisciplinary national and multinational health care / service research and projects implementation and monitoring and evaluations. He was a member of the Pneumococcal Polysaccharide Conjugate Vaccine Trial team with the Medical Research Council Laboratories in The Gambia where he designed and implemented the economic evaluation component of the trial.
Within Surrey Health Economics Centre (SHEC), he works on a variety of externally funded applied health projects. He coordinates the links between SHEC and School of Veterinary Sciences in our global research engagements. His current and recent research projects and clinical trials encompass areas of cancer, nutrition, liver diseases, alcohol misuse, Parkinson’s disease and zoonotic diseases to name a few.
In pursuit of his Global Health Research interests, he was instrumental in the establishment of Surrey Global Health Research Network which has members from Europe, Asia, Middle East, South America and Africa all with outstanding research backgrounds. He is currently coordinating the network.
In the area of Development works, he was involved in the design, implementation and evaluation of many development programmes at grassroots and national levels. He led the UNDP’s project on the establishment of the National Planning Commission (NPC) for the Government of The Gambia. NPC was the apex body responsible for coordination of national development strategies and all planning matters at central, sector and decentralised levels. He also initiated and led many nationwide research activities including poverty and social impact analysis study which was on access to healthcare and basic education.
Affiliations and memberships
2. The International Association for the Study of Obesity (IASO)
3. Scottish Health Economics (SHE)
Economic analysis along clinical trials; global health; zoonotic, tropical and infectious diseases modelling; health policy and systems in low income and developing countries; health services and health outcomes research; health technology assessment; evidence synthesis for decision making in healthcare; obesity; understanding of behavioural dimension of diseases (including cultural and traditional practices) and their influence on healthcare resources.
Objectives? To evaluate the cost effectiveness of the use of nine-valent pneumococcal polysaccharide conjugate vaccine in a routine infant immunisation programme based on the Pneumococcal Vaccine Trial (PVT) study in The Gambia.
Methods? This was a clinical trial-based cost-effectiveness study conducted as part of the PVT study. The PVT was an intention-to-treat double-blind placebo-controlled trial of a nine-valent pneumococcal polysaccharide conjugate vaccine. The trial was conducted in the eastern parts of The Gambia, West Africa and recruited 17 437 children aged 40?364 days. A deterministic static cohort model was developed to evaluate direct benefits and costs of pneumococcal conjugate vaccine in The Gambia's routine immunisation programme. The incremental cost-effectiveness ratio (iCER) is defined as vaccinating infants against pneumococcal disease compared with no vaccination from a public provider's perspective using The Gambia's 2005 projected under-one-year population.
Key findings? The results show the use of the vaccine in The Gambia's routine infant vaccination programme to be cost effective using an assumed price of US$5.00 per vial in single-dose vials. Compared with offering no vaccination, the incremental cost per DALYs averted would be 30 DALYs from the public provider perspective. At least 1569 and 340 invasive childhood pneumococcal illnesses and deaths respectively among the cohort would be prevented. In the absence of the vaccine 16 871 DALYs would be lost while with the use of the vaccine 7804 DALYs would be lost. Given the average treatment cost of pneumococcal illnesses to be US$191 (95% confidence interval 180 to 203) the introduction of the vaccine programme would lead to an additional cost of US$274 279 (about US$8.43/child).
Conclusions? The availability of a cost-effective vaccine that can prevent thousands of pneumococcal illnesses and related deaths is a major development towards improving the disease burden in sub-Saharan African countries. This study supports the introduction of nine-valent pneumococcal vaccine into the infant immunisation programme of The Gambia as it is cost effective and will avert many preventable deaths and illnesses. Despite differences in distribution of serotypes between countries, the static model used in the analysis makes the results applicable to other developing countries, particularly those in sub-Saharan Africa.
The objectives were to investigate the impact of ?time-effect? on the estimation of quality-adjusted life years (QALYs) along prospective clinical trials? outcomes using an assumed fixed time duration versus the actual time durations for each case. The ?time? duration is the length of time in a health state.
Two methods were used in the estimation of QALYs based using EQ-5D 3L scores collected at specific time-point intervals. One method used the actual time durations for each case based on CRF records, and the other used an assumed time duration and globally applied it to all the cases. Using SPSS® software program, we used paired-sample t-tests to assess whether the ?time-effect? can potentially affect trial results using CONSTRUCT trial data as reported in the trial results publications. The trial compared use of Infliximab with Cyclosporine for patients with Ulcerative Colitis and it involved some 270 participants.
The results largely indicate statistically significant differences between the two methods of QALY estimations. QALYs at the respective time-points indicate no statistical difference between the two approaches. However, the difference in terms of total QALYs between the two QALY estimation approaches is statistically significant with considerable impact on costs/QALY.
Considering the possible impact of the time-effect on QALY estimations, the result implies that it can have significant implications for resources allocations decisions. In this respect, researchers have to pay due considerations to the approach they use and where possible, actual time durations must be used in QALY estimations along prospective clinical trials.
symptoms that have a serious adverse effect on quality of life. Management is problematic due to the variable and
fluctuating nature of symptoms, often hourly and daily. The PD_Manager mHealth platform aims to provide a
continuous feed of data on symptoms to improve clinical understanding of the status of any individual patient and
inform care planning. The objectives of this trial are to (1) assess patient (and family carer) perspectives of PD_
Manager regarding comfort, acceptability and ease of use; (2) assess clinician views about the utility of the data
generated by PD_Manager for clinical decision making and the acceptability of the system in clinical practice.
Methods/design: This trial is an unblinded, parallel, two-group, randomised controlled pilot study. A total of 200
persons with Parkinson?s disease (Hoehn and Yahr stage 3, experiencing motor fluctuations at least 2 h per day),
with primary family carers, in three countries (110 Rome, 50 Venice, Italy; 20 each in Ioannina, Greece and Surrey,
England) will be recruited. Following informed consent, baseline information will be gathered, including the
following: age, gender, education, attitudes to technology (patient and carer); time since Parkinson?s diagnosis,
symptom status and comorbidities (patient only). Randomisation will assign participants (1:1 in each country), to
PD_Manager vs control, stratifying by age (1 d 70 : 1 > 70) and gender (60% M: 40% F). The PD_Manager system
captures continuous data on motor symptoms, sleep, activity, speech quality and emotional state using wearable
devices (wristband, insoles) and a smartphone (with apps) for storing and transmitting the information. Control
group participants will be asked to keep a symptom diary covering the same elements as PD_Manager records.
After a minimum of two weeks, each participant will attend a consultation with a specialist doctor for review of the
data gathered (by either means), and changes to management will be initiated as indicated. Patients, carers and
clinicians will be asked for feedback on the acceptability and utility of the data collection methods. The PD_
Manager intervention, compared to a symptom diary, will be evaluated in a cost-consequences framework Discussion: Information gathered will inform further development of the PD_Manager system and a larger
Trial registration: ISRCTN Registry, ISRCTN17396879. Registered on 15 March 2017.
Objective: Complex cardiac devices including implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy (CRT) devices can safely be implanted as a day case procedure as opposed to overnight stay. We assess how common day case complex device therapy is and the cost implications of more widespread adoption across the UK.
Methods: A freedom of information request was sent to all centres performing complex cardiac devices across the UK to assess the adoption of this technique. Cost implications were assessed using Department of Health National Schedule of Reference Costs 2016?2017.
Results: 100 UK centres were surveyed, 80% replied. Eighty per cent of UK centres already implant complex cardiac devices as a day case to some extent. 64.06% of centres have a protocol for this. 12.82% of centres do Â25% of complex devices as a day case. 15.38% do 25%?50% as day case. 17.95% do 50%?75% as day case and 33.33% do Ã75% as day case. There was no relationship between centre volume and the proportion of devices done as a day case as opposed to overnight stay. The cost saving of performing a complex device as a day case as opposed to overnight stay was £412 per ICD, £525 per CRT-pacemaker and £2169 per CRT-defibrillator.
Conclusions: Day case complex devices are already widespread across the UK, however, there is scope for increase. An increase in proportion of day case devices could translate to £5 583 265 in savings annually for the National Health Service if all centres performed 75% of devices as a day case.
Background and aims: Ascites develops in about 90% with advanced
cirrhosis; when refractory to medical therapy, standard of care is
repeated large volume paracentesis (LVP) with albumin support.
Refractory ascites (RA) confers a median life expectancy of six months
without liver transplantation (LT). LVP is not an optimal palliative
strategy. One alternative is long-term abdominal drains (LTAD), used
in advanced malignant ascites, also enabling community management. Our ultimate aim is to improve end of life care (EoLC) in
advanced cirrhosis and RA. This feasibility randomised controlled
trial (RCT) aimed to resolve uncertainties in designing a definitive
Method: Multicentre feasibility RCT with 1:1 randomisation between
standard of care (LVP) vs. LTAD (Rocket Medical) in adults with RA,
ineligible for LT. Both arms received prophylactic antibiotics. LTAD
were inserted under ultrasound guidance. Community nurses
undertook home visits to drain ascites dependent on symptoms;
(maximum 6L/week), without albumin support. Follow-up was 12
weeks with home visits every two weeks for the following
assessments: clinical, questionnaire based to include quality of life,
palliative care needs, carer burden and health economics (HE). Here
we report clinical and HE outcomes.
Results: Thirty six patients were randomised; 19 LVP (two withdrew,
wanting LTAD) and 17 LTAD (one withdrew-insufficient ascites). Mean
age (years) LTAD vs. LVP 66 + 10.4 vs. 68 ± 12; predominately male
(76% vs. 74%). Participants were well matched at baseline in liver tests
and prognostic scores: LTAD vs. LVP (serum bilirubin (¼mol/L) 26 ±
15.8 vs. 16 ±10, serum albumin (g/L) 33 ± 4.2 vs. 31 ± 3.3, serum
creatinine (mmol/L) 113 ± 46.7 vs.118 ± 53.1; MELD 14 ± 4.6 vs. 16 ±
7.2). One LTAD participant required hospitalisation for repeated LVP.
Serum albumin (g/L) in the LTAD arm declined to 29 ± 3.3 at week
two, subsequently remaining stable LTAD vs. LVP (29 ± 5.6 vs. 31 ±
5.5). Serum creatinine remained stable in both arms. There were no
LTAD related serious adverse reactions. LTAD related adverse reactions
included mild cellulitis (n = 4) and small volume leakage around LTAD
insertion site (n = 3), all resolving rapidly. Peritonitis was rare, LTAD
(possible) n = 1 and LVP n = 2. Overall mortality was 36% (12/33).
Mortality and median survival (days in those who died) were 7/16
(44%) vs. 5/17 (29%), 53 days (IQR 43) vs. 61 days (IQR 35) in LTAD vs.
LVP respectively. All but one death was liver related. Those in LTAD
arm spent H20% less time in hospital. All nine alive in the LTAD arm at
end of study elected to keep LTAD in. Detailed clinical and HE analysis
Conclusion: Preliminary data from the REDUCe study supports the
safety and efficacy of palliative LTAD in RA due to advanced cirrhosis.
LTAD allows successful management in the community with
reduction in health resource utilisation. Proceeding to a definitive
RCT is justified.
Methods: A suite of user needs studies was conducted in 4 European countries (Greece, Italy, Slovenia, the UK) prior to the development of PD_Manager, a mHealth-based CDSS designed for Parkinson?s Disease, using wireless technology. Study 1 undertook Hierarchical Task Analysis (HTA) including elicitation of user needs, cognitive demands and perceived risks/benefits (ethical considerations) associated with the proposed CDSS, through structured interviews of prescribing clinicians (N=47). Study 2 carried out computational modelling of prescribing clinicians? (N=12) decision strategies based on social judgment theory. Study 3 was a vignette study of prescribing clinicians? (N=18) willingness to change treatment based on either self-reported symptoms data, devices-generated symptoms data or combinations of both.
Results: Study 1 indicated that system development should move away from the traditional silos of ?motor? and ?non-motor? symptom evaluations and suggest that presenting data on symptoms according to goal-based domains would be the most beneficial approach, the most important being patients? overall Quality of Life (QoL). The computational modelling in Study 2 extrapolated different factor combinations when making judgements about different questions. Study 3 indicated that the clinicians were equally likely to change the care plan based on information about the change in the patient?s condition from the patient?s self-report and the wearable devices.
Conclusions: Based on our approach, we could formulate the following principles of mHealth design: 1) enabling shared decision making between the clinician, patient and the carer; 2) flexibility that accounts for diagnostic and treatment variation among clinicians; 3) monitoring of information integration from multiple sources. Our approach highlighted the central importance of the patient-clinician relationship in clinical decision making and the relevance of theoretical as opposed to algorithm (technology)-based modelling of human judgment.